Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease among US Adults with Diabetes

Michael C. Honigberg; Ravi B. Patel; Ambarish Pandey; Gregg C. Fonarow; Javed Butler; Darren K. McGuire; Muthiah Vaduganathan

doi:10.1001/jamacardio.2020.5921

Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease among US Adults with Diabetes

Michael C. Honigberg, Ravi B. Patel, Ambarish Pandey, Gregg C. Fonarow, Javed Butler, Darren K. McGuire, Muthiah Vaduganathan

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	354-357
Number of pages	4
Journal	JAMA Cardiology
Volume	6
Issue number	3
DOIs	https://doi.org/10.1001/jamacardio.2020.5921
State	Published - Mar 2021
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2020.5921

Cite this

@article{f97f59d0e9d641c78fbe14c703fb6b9b,

title = "Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease among US Adults with Diabetes",

author = "Honigberg, {Michael C.} and Patel, {Ravi B.} and Ambarish Pandey and Fonarow, {Gregg C.} and Javed Butler and McGuire, {Darren K.} and Muthiah Vaduganathan",

note = "Funding Information: Conflict of Interest Disclosures: Dr Cariou reported grants, personal fees, and nonfinancial support from Amgen and Sanofi; grants from Pfizer; grants and personal fees from Regeneron; personal fees and nonfinancial support from Merck (MSD); and personal fees from Akcea outside the submitted work. No other disclosures were reported. Funding/Support: Dr Rimbert is supported by a postdoctoral fellowship grant from the Institut de France-Fondation Lefoulon-Delalande. This work was supported by the French national research project CHOPIN (CHolesterol Personalized INnovation) funded by the Agence Nationale de la Recherche (ANR-16-RHUS-0007) and coordinated by the CHU of Nantes. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank all participants of these different cohorts and authors that made genetic and genomic data available. We thank Bahram Namjou, MD, Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, who kindly shared genetic data from his association study.5 No compensation was received from a funding source for these contributions. We acknowledge the use of data from UK-biobank cohort (https://www.ukbiobank.ac.uk) and from eMERGE cohort (https://emerge-network.org). Funding Information: National Institutes of Health outside the submitted work. Dr Fonarow reports research funding from the National Institutes of Health and personal fees from Abbott Laboratories, Amgen, AstraZeneca, Bayer, CHF Solutions, Janssen, Medtronic, Merck, and Novartis outside the submitted work. Dr Butler reports research support from the National Institutes of Health, Patient-Centered Outcomes Research Institute, and the European Union outside the submitted work and serves as a consultant for Amgen, Abbott Laboratories, Array BioPharma, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, American Regent, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, scPharmaceuticals, Vifor Pharma, and ZS Pharma. Dr McGuire reports personal fees and honoraria for trial leadership and consultancy from Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co, Novo Nordisk, and Eli Lilly and Co; for trial leadership from CSL Behring, Pfizer, Lexicon, and GlaxoSmithKline; and for consultancy from Applied Therapeutics, Metavant, and Afimmune outside the submitted work. Dr Vaduganathan has received a KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst and personal fees for consulting for or serving on the advisory boards of Amgen, AstraZeneca, Baxter Healthcare, Bayer, Boehringer Ingelheim, Cytokinetics, and Relypsa outside the submitted work, and participates on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. No other disclosures were reported. Funding Information: Funding/Support: Dr Honigberg is supported by grant T32HL094301-07 from the National Heart, Lung, and Blood Institute. Dr Patel supported by grant T32HL069771 from the National Heart, Lung, and Blood Institute. Dr Pandey is supported by the Texas Health Resources Clinical Scholars Program.",

year = "2021",

month = mar,

doi = "10.1001/jamacardio.2020.5921",

language = "English (US)",

volume = "6",

pages = "354--357",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease among US Adults with Diabetes

AU - Honigberg, Michael C.

AU - Patel, Ravi B.

AU - Pandey, Ambarish

AU - Fonarow, Gregg C.

AU - Butler, Javed

AU - McGuire, Darren K.

AU - Vaduganathan, Muthiah

N1 - Funding Information: Conflict of Interest Disclosures: Dr Cariou reported grants, personal fees, and nonfinancial support from Amgen and Sanofi; grants from Pfizer; grants and personal fees from Regeneron; personal fees and nonfinancial support from Merck (MSD); and personal fees from Akcea outside the submitted work. No other disclosures were reported. Funding/Support: Dr Rimbert is supported by a postdoctoral fellowship grant from the Institut de France-Fondation Lefoulon-Delalande. This work was supported by the French national research project CHOPIN (CHolesterol Personalized INnovation) funded by the Agence Nationale de la Recherche (ANR-16-RHUS-0007) and coordinated by the CHU of Nantes. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank all participants of these different cohorts and authors that made genetic and genomic data available. We thank Bahram Namjou, MD, Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, who kindly shared genetic data from his association study.5 No compensation was received from a funding source for these contributions. We acknowledge the use of data from UK-biobank cohort (https://www.ukbiobank.ac.uk) and from eMERGE cohort (https://emerge-network.org). Funding Information: National Institutes of Health outside the submitted work. Dr Fonarow reports research funding from the National Institutes of Health and personal fees from Abbott Laboratories, Amgen, AstraZeneca, Bayer, CHF Solutions, Janssen, Medtronic, Merck, and Novartis outside the submitted work. Dr Butler reports research support from the National Institutes of Health, Patient-Centered Outcomes Research Institute, and the European Union outside the submitted work and serves as a consultant for Amgen, Abbott Laboratories, Array BioPharma, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, American Regent, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, scPharmaceuticals, Vifor Pharma, and ZS Pharma. Dr McGuire reports personal fees and honoraria for trial leadership and consultancy from Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co, Novo Nordisk, and Eli Lilly and Co; for trial leadership from CSL Behring, Pfizer, Lexicon, and GlaxoSmithKline; and for consultancy from Applied Therapeutics, Metavant, and Afimmune outside the submitted work. Dr Vaduganathan has received a KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst and personal fees for consulting for or serving on the advisory boards of Amgen, AstraZeneca, Baxter Healthcare, Bayer, Boehringer Ingelheim, Cytokinetics, and Relypsa outside the submitted work, and participates on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. No other disclosures were reported. Funding Information: Funding/Support: Dr Honigberg is supported by grant T32HL094301-07 from the National Heart, Lung, and Blood Institute. Dr Patel supported by grant T32HL069771 from the National Heart, Lung, and Blood Institute. Dr Pandey is supported by the Texas Health Resources Clinical Scholars Program.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85097097913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097097913&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2020.5921

DO - 10.1001/jamacardio.2020.5921

M3 - Letter

C2 - 33237259

AN - SCOPUS:85097097913

SN - 2380-6583

VL - 6

SP - 354

EP - 357

JO - JAMA Cardiology

JF - JAMA Cardiology

IS - 3

ER -

Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease among US Adults with Diabetes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this